Pancreatic Exocrine Dysfunction Associated with Mitochondrial Trnaieu(UR) Mutation J Med Genet: First Published As 10.1136/Jmg.35.3.255 on 1 March 1998

Total Page:16

File Type:pdf, Size:1020Kb

Pancreatic Exocrine Dysfunction Associated with Mitochondrial Trnaieu(UR) Mutation J Med Genet: First Published As 10.1136/Jmg.35.3.255 on 1 March 1998 J Med Genet 1998;35:255-257 255 Pancreatic exocrine dysfunction associated with mitochondrial tRNAIeu(UR) mutation J Med Genet: first published as 10.1136/jmg.35.3.255 on 1 March 1998. Downloaded from Hideki Onishi, Tokiji Hanihara, Naoya Sugiyama, Chiaki Kawanishi, Eizo Iseki, Yasuko Maruyama, Yoshiteru Yamada, Kenji Kosaka, Saburo Yagishita, Hisahiko Sekihara, Shinobu Satoh Abstract Family C. The proband (C-I) is a 55 year old We report on pancreatic exocrine dys- woman with a history ofDM from the age of 53 function in families that have the mito- years. Her son (C-II), aged 25, developed chondrial tRNAIAu(UR) gene mutation. stroke-like episodes and haemianopia at the These families exhibited maternally in- age of 21 and was diagnosed as having herited diabetes mellitus (DM) and an A MEIAS. He was further diagnosed as having to G substitution at nt 3243 of the DM at the age of 23. The clinical symptoms mitochondrial tRNAutu) gene (A3243G and molecular genetic analysis ofA-II and B-II mutation). Pancreatic necropsy samples have been described in previous reports.78 from one proband showed accumulation As a test of exocrine pancreatic function, we of degenerated mitochondria in pancre- performed a bentiromide test using benzoyl- atic acinar cells. Pancreatic exocrine dys- tyrosyl-p-aminobenzoic acid (Bz-Ty-PABA, function was recognised by a functional PFD oral, Eisai Co Ltd)9 on the probands and pancreatic study. This study indicates that their sons in families B and C, as they were the exocrine pancreatic dysfunction may be only ones who agreed to the test. The test was associated with the A3243G mutation. performed according to the manufacturer's (7Med Genet 1998;35:255-257) instructions. Results were expressed as per- centage recovery of PABA in urine (normal Keywords: mitochondrial DNA; pancreatic exocrine range=81.9±8.5% in non-diabetic subjects and dysfunction; bentiromide test 77±12.6% in diabetic patients).10" We could not perform the test on the proband in family A Many mitochondrial DNA (mtDNA) muta- (A-II) because of his poor condition. tions are associated with various diseases.' One Genomic DNA extraction, PCR amplifica- of the most common mutations involves an A tion, restriction enzyme analysis, sequencing, to G substitution at nt 3243 of the tRNAI'u'(R) and densitometric analysis were performed as of gene (A3243G mutation).2 Recent studies have previously described.8 Department http://jmg.bmj.com/ Psychiatry, Yokohama shown that there is a close association between The pathological findings of the pancreas of City University School the A3243G mutation and maternally inher- patient A-II at necropsy are as follows. The ofMedicine, 3-9 ited DM.' Multiorgan involvement has also pancreas showed no acinar atrophy or fibrosis. Fukuura, In the pancreatic acini, degenerative acinar Kanazawa-ku, been suggested.4 However, pancreatic exocrine Yokohama City, dysfunction has not been investigated, al- cells with pycnotic nuclei were found to be Kanagawa 236, Japan though it has been reported in patients with scattered or clustered. As determined by H Onishi mtDNA deletion.5 6Here, we report on pancre- electron microscopy, these cells had lost most T Hanihara atic exocrine dysfunction in families with the of the rough endoplasmic reticulum, Golgi on September 25, 2021 by guest. Protected copyright. N Sugiyama apparatus, and secretory granules, and were C Kawanishi A3243G mutation. E Iseki Clinical characteristics of the family mem- occupied by closely congregated vacuolar Y Maruyama bers are as follows (fig 1). mitochondria (fig 2). No dilatation of the ducts Y Yamada Family A. The proband (A-II), a 39 year old or liposis was present. The number ofislets was K Kosaka man, was diagnosed as having DM at the age of markedly decreased. 29 years. He developed stroke-like episodes Molecular genetic analysis of the five pa- Department of muta- Pathology, Kanagawa and was diagnosed with mitochondrial myopa- tients showed that they had an A3243G Rehabilitation Centre, thy, encephalopathy, lactic acidosis, and stroke- tion to different degrees. Densitometric analy- Japan like episodes (MELAS) at the age of 31 years. sis showed the percentage of mutant mtDNA S Yagishita He continued to experience stroke-like epi- in the white blood cells and the necropsy sam- sodes. In the later stages of the disease, he had ples ranged from 6% to 63% (fig 1). of Department at age A The five patients showed normal serum Internal Medicine, chronic diarrhoea. He died the of 39. Yokohama City necropsy was performed six hours after death. amylase and lipase levels. The bentiromide test University School of Family B. The proband (B-I) is a 52 year old indicated that three ofthe four patients showed Medicine, Japan woman with a history ofDM from the age of 50 a decreased percentage recovery of PABA, S Satoh years. The proband's son (B-II), aged 24 years, which in patients B-I, B-II, C-I, and C-II was H Sekihara has had Wolff-Parkinson-White syndrome 68%, 19%, 50%, and 40%, respectively. age years, a decrease in The present study showed pancreatic exo- Correspondence to: since the of 5 slight Dr Onishi. hearing threshold from the age of 20, and crine dysfunction in families with the A3243G developed impaired glucose tolerance at the mutation. Although DM is commonly associ- Received 24 April 1997 age of 24. The proband's mother, aged 83 ated with the A3243G mutation, exocrine pan- Revised version accepted for publication 5 September years, has had DM since the age of 73 and sen- creatic dysfunction is not a recognised feature. 1997 sory hearing disturbance from the age of 80. However, it is worth noting that a significant 256 Onishi, Hanihara, Sugiyama, et al degree of exocrine pancreatic dysfunction is a I'I. feature of Pearson syndrome (McKusick No 26056), a disease associated with deletions of A mtDNA.56 J Med Genet: first published as 10.1136/jmg.35.3.255 on 1 March 1998. Downloaded from The electron microscopic appearance at necropsy of the pancreas of patient A-II is characteristic. Accumulation of vacuolar mito- chondria seen in degenerative acinar cells is analogous to that seen in skeletal and cardiac muscle cells'2 13 as well as smooth muscle and ri i_endothelial cells of the cerebral vessels'4 of patients with mitochondrial encephalomyopa- thy. These findings led us to investigate pancreatic exocrine function. .L= B~The percentage recovery of PABA was variable between patients regardless of age. The clinical phenotype of mitochondrial dis- ease depends on the level of heteroplasmy in -2 each organ, organ threshold, and age.'5 16 In our patients, the percentage of mutant mtDNA in the exocrine pancreas may be different. -_ 1SL Pancreatic exocrine dysfunction was recog- nised only by the bentiromide test, which is non-invasive and has a significant correlation with the results of the pancreozymin secretin test.9 However, the bentiromide test showed relatively little impairment. These data, to- IC ^7 6 A2 VI; !-tr !: gether with the minimal changes in pancreatic cell morphology, indicate that the pancreatic exocrine dysfunction in these patients is subtle. One patient (A-II) showed chronic diarrhoea in the later stages of the disease. This might have V71-7 777-71 resulted from steatorrhoea, although this was M Ei-Pp%;,-'---'. -, i iI t [i Z'i !i, i-. .< :iiLll ;.-. r.-zjIt, not documented clinically. In conclusion, we observed variable clinical symptoms in the patients and our results indi- -cate that exocrine pancreatic dysfunction may 60MELF h , ! , be associated with the A3243G mutation. IL.4z http://jmg.bmj.com/ "x!IaI\ iit /aIIIihI - This work was supported by a research grant from the UNIVERS foundation to HO and from the Japanese Ministry of Education, Science and Culture (C-0967048) to SS. We are grateful to Dr Ken Inoue, Dr Kyoko Suzuki, Dr Tomohiro Miyakawa (Department of Psychiatry, Yokohama City Univer- Figure 1 Identification and quantitation of the A3243G mutation ofthe mitochondrial sity), Dr Hitoshi Osaka, and Professor Palmer Taylor (Depart- tRNAI,e(UUR) gene in white blood cells (B) ofall the patients and ofthe quadriceps muscle ment of Pharmacology, University of California, San Diego) for (Q) andpancreas (P) ofnecropsy samplesfrom patient A-II. The percentage of mutant their kind suggestions, without whose cooperation this work mtDNA and the percentage recovery ofPABA are shown. M: size marker. would not have been possible. on September 25, 2021 by guest. Protected copyright. 1 DiMauro S, Moraes CT. Mitochondrial encephalomyopa- thies. Arch Neurol 1993;50:1 198-208. 2 Hammans SR, Sweeney MG, Hanna MG, et al. The mitochondrial DNA transfer RNA'Lu('") A-G(.3243I muta- tion. Brain 1995;118:21-34. 3 van den Ouweland JMW, Lemkes HHPJ, Ruitenbeek W, et al. Mutation in mitochondrial tRNA!-lUUR) gene in a large pedigree with maternally transmitted type II diabetes and deafness. Nat Genet 1992;1:368-71. 4 Maassen JA, Kadowaki T. Maternally inherited diabetes and deafness: a new diabetes subtype. Diabetologia 1996;39: 375-82. 5 Pearson HA, Lobel JS, Kocoshis S, et al. A new syndrome of ... sideroblastic anemia with vacuolation of marrow precur- sors and exocrine pancreatic dysfunction. Jf Pediatr .g. !.. ... ., 1979;95:976-84. 6 Rotig A, Colonna M, Bonnefont JP, et al. Mitochondrial w s~~~~~~~~~~~~~~~~~~~... .w,,.., DNA deletion in Pearson's marrow/pancreas syndrome. Lancet 1989;i:902-3. 7 Onishi H, Inoue K, Osaka H, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes <Xn4DI>i'*'~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~........0M (MELAS) and diabetes mellitus: molecular genetic analysis and family study. _J Neurol Sci 1993 114:205-8. 8 Onishi H, Kawanishi C, Iwasawa T, et al. Depressive disor- der due to mitochondrial tRNAIu(UUR) mutation.
Recommended publications
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • 4-Aminobenzoic Acid (PABA)
    SCCP/1008/06 EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON CONSUMER PRODUCTS SCCP Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1 Adopted by the SCCP during the 8th plenary meeting of 20 June 2006 SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ TABLE OF CONTENTS 1. BACKGROUND ………………………………………………… 3 2. TERMS OF REFERENCE ……………………………………………….... 3 3. OPINION ………………………………………………… 4 4. CONCLUSION ………………………………………………… 48 5. MINORITY OPINION ………………………………………………… 48 6. REFERENCES ………………………………………………… 48 7. ACKNOWLEDGEMENTS ………………………………………………… 56 2 SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 1. BACKGROUND PABA or 4-Aminobenzoic acid (PABA) is listed in Annex VII part 1 no. 1 on the List of permitted UV filters that may be used in cosmetic products. The maximum authorised concentration in finished cosmetic products is 5 %. No other limitations and requirements or conditions of use and warnings are required by the SCCP. In 2001, the Commission received inquiries from Denmark expressing its concern about the use of certain UV filters in cosmetic products. In this connection an opinion on PABA was missing, as the substance has been introduced into the Annexes of the cosmetics legislation based on safety evaluations from the Member States prior to the existence of the SCCNFP. Submission I on the UV-filter 4-Aminobenzoic acid (PABA) was submitted December 2005. 2. TERMS OF REFERENCE 1. Is 4-Aminobenzoic acid (PABA) safe for continued use as a UV filter in cosmetic products under the current restriction of 5.0 % as a maximum concentration? 2. Does the SCCP consider that the use of 4-Aminobenzoic acid (PABA) is safe for the consumer in a concentration up to 5 % when used in other cosmetic products than sunscreen products? 3.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]
  • Chronic Pancreatitis: Introduction
    Chronic Pancreatitis: Introduction Authors: Anthony N. Kalloo, MD; Lynn Norwitz, BS; Charles J. Yeo, MD Chronic pancreatitis is a relatively rare disorder occurring in about 20 per 100,000 population. The disease is progressive with persistent inflammation leading to damage and/or destruction of the pancreas . Endocrine and exocrine functional impairment results from the irreversible pancreatic injury. The pancreas is located deep in the retroperitoneal space of the upper part of the abdomen (Figure 1). It is almost completely covered by the stomach and duodenum . This elongated gland (12–20 cm in the adult) has a lobe-like structure. Variation in shape and exact body location is common. In most people, the larger part of the gland's head is located to the right of the spine or directly over the spinal column and extends to the spleen . The pancreas has both exocrine and endocrine functions. In its exocrine capacity, the acinar cells produce digestive juices, which are secreted into the intestine and are essential in the breakdown and metabolism of proteins, fats and carbohydrates. In its endocrine function capacity, the pancreas also produces insulin and glucagon , which are secreted into the blood to regulate glucose levels. Figure 1. Location of the pancreas in the body. What is Chronic Pancreatitis? Chronic pancreatitis is characterized by inflammatory changes of the pancreas involving some or all of the following: fibrosis, calcification, pancreatic ductal inflammation, and pancreatic stone formation (Figure 2). Although autopsies indicate that there is a 0.5–5% incidence of pancreatitis, the true prevalence is unknown. In recent years, there have been several attempts to classify chronic pancreatitis, but these have met with difficulty for several reasons.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Simplified Oral Pancreatic Function Test
    Arch Dis Child: first published as 10.1136/adc.63.7.780 on 1 July 1988. Downloaded from Archives of Disease in Childhood, 1988, 63, 780-784 Simplified oral pancreatic function test J W L PUNTIS,* J D BERG,t B M BUCKLEY,t I W BOOTH,* AND A S McNEISH* *Institute of Child Health, University of Birmingham, Birmingham Children's Hospital, and tDepartment of Clinical Biochemistry, Sandwell District General Hospital, West Bromwich, West Midlands SUMMARY The standard Bentiromide test and a new modified test using p-aminosalicylic acid (PAS) as a pharmacokinetic marker for p-aminobenzoic acid (PABA) have been evaluated in the detection of pancreatic exocrine insufficiency in children. The conventional two day test using a colorimetric assay for urinary PABA discriminated poorly between five children with pancreatic insufficiency and 13 others with normal pancreatic function. Two further groups of patients, comprising 28 with pancreatic exocrine insufficiency and 20 with normal pancreatic function underwent the modified test, and urine samples were analysed by high performance liquid chromatography. The results showed a complete separation between groups. The use of PAS eliminates a number of sources of error inherent in a two day Bentiromide test and provides a simplified and accurate diagnostic test for pancreatic insufficiency. The PABA-PAS modified test enables collection of the urine to be done during a single six hour period. Exocrine pancreatic insufficiency is often considered ordered gut motility or an enteropathy (which result in the differential diagnosis of failure to thrive, in low PABA absorption) or in those with hepatic or protracted diarrhoea, or steatorrhoea.
    [Show full text]
  • Human Pancreatic Exocrine Response to Nutrients in Health and Disease
    vi1 REVIEW Human pancreatic exocrine response to nutrients in health Gut: first published as 10.1136/gut.2005.065946 on 10 June 2005. Downloaded from and disease J Keller, P Layer ............................................................................................................................... Gut 2005;54(Suppl VI):vi1–vi28. doi: 10.1136/gut.2005.065946 1.0 INTRODUCTION exocrine response to various endogenous stimuli. Optimal digestion and absorption of nutrients This chapter will summarise literature data on requires a complex interaction among motor and pancreatic exocrine response to a normal diet, its secretory functions of the gastrointestinal tract. physical and biochemical properties, and to Digestion of macronutrients is a prerequisite for administration of individual food components absorption and occurs mostly via enzymatic in healthy humans with respect to total pan- hydrolysis. In this context, pancreatic enzymes, creatic secretion, secretion of individual in particular lipase, amylase, trypsin, and chy- enzymes, ratios of enzymes, intraluminal pH motrypsin, play the most important role but and bicarbonate and bile acid secretion. several brush border enzymes as well as other pancreatic and extrapancreatic enzymes also 2.2 Pancreatic response to a normal diet participate in macronutrient digestion. The cru- In the fasting state, human pancreatic exocrine cial importance of pancreatic exocrine function is secretion is cyclical and closely correlated with reflected by the detrimental malabsorption in upper gastrointestinal
    [Show full text]
  • Feline Exocrine Pancreatic Disease
    Feline Health Topics for veterinarians Volume 10, Number 4 Feline Exocrine Pancreatic Disease David A. Williams, M.A., Vet. MB, Ph.D., DACVIM and Jorg M. Steiner, med. vet., Dr. med. vet. Traditionally, the frequency of exocrine pancreatic bladder and pancreatic parasites (i.e., Eurytrema disease in cats has been considered to be low. How­ procyonis and Amphimerus pseudofelineus). ever, a recent study has shown that the frequency of The following discussion focuses on pancreatitis significant pathologic lesions of the exocrine pan­ and exocrine pancreatic insufficiency. Limited evi­ creas at necropsy is almost as high in cats as it is in dence shows that while there are broad similarities dogs (1.4 % in cats and 1.7 % in dogs).1 Other studies between these diseases in cats and dogs, there are also report even higher frequencies.2,3 This is contrasted some important differences, particularly with regard by an infrequent clinical diagnosis of exocrine pan­ creatic diseases in cats. Cats suffer from various to etiology and diagnostic testing. exocrine pancreatic diseases. However, the most Pancreatitis common condition appears to be pancreatitis. Chronic forms of pancreatitis are more common than acute Recent reports have described that acute necrotizing forms. Exocrine pancreatic insufficiency and pan­ pancreatitis in cats is similar to that seen in dogs, as creatic neoplasia are less common than inflammatory well as a histologically distinct suppurative form.4 disease. Finally, other conditions have been reported This contrasts with traditional reports of chronic mild in the cat such as pancreatic pseudocyst, pancreatic interstitial pancreatic inflammation in cats, charac­ terized by inflammation of interstitial tissue appar­ ently spreading from the ducts, often accompanied by cholangiohepatitis, and sometimes by interstitial nephritis.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]